351 related articles for article (PubMed ID: 28938163)
1. Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma.
Liang C; Li F; Wang L; Zhang ZK; Wang C; He B; Li J; Chen Z; Shaikh AB; Liu J; Wu X; Peng S; Dang L; Guo B; He X; Au DWT; Lu C; Zhu H; Zhang BT; Lu A; Zhang G
Biomaterials; 2017 Dec; 147():68-85. PubMed ID: 28938163
[TBL] [Abstract][Full Text] [Related]
2. Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA.
Zhang X; Jin H; Huang X; Chaurasiya B; Dong D; Shanley TP; Zhao YY
Cell Rep; 2022 Jan; 38(1):110196. PubMed ID: 34986352
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome.
Zhen S; Takahashi Y; Narita S; Yang YC; Li X
Oncotarget; 2017 Feb; 8(6):9375-9387. PubMed ID: 28030843
[TBL] [Abstract][Full Text] [Related]
4. Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology.
Bai B; Myklebust JH; Wälchli S
Methods Mol Biol; 2020; 2115():445-454. PubMed ID: 32006416
[TBL] [Abstract][Full Text] [Related]
5. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-gRNA Design.
Pallarès Masmitjà M; Knödlseder N; Güell M
Methods Mol Biol; 2019; 1961():3-11. PubMed ID: 30912036
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
Vermersch E; Jouve C; Hulot JS
Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Cas9 in genome editing: Its function and medical applications.
Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM
J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544
[TBL] [Abstract][Full Text] [Related]
9. Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.
Kelkar A; Zhu Y; Groth T; Stolfa G; Stablewski AB; Singhi N; Nemeth M; Neelamegham S
Mol Ther; 2020 Jan; 28(1):29-41. PubMed ID: 31601489
[TBL] [Abstract][Full Text] [Related]
10. PEG-Delivered CRISPR-Cas9 Ribonucleoproteins System for Gene-Editing Screening of Maize Protoplasts.
Sant'Ana RRA; Caprestano CA; Nodari RO; Agapito-Tenfen SZ
Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32887261
[TBL] [Abstract][Full Text] [Related]
11. Developing Heritable Mutations in Arabidopsis thaliana Using a Modified CRISPR/Cas9 Toolkit Comprising PAM-Altered Cas9 Variants and gRNAs.
Yamamoto A; Ishida T; Yoshimura M; Kimura Y; Sawa S
Plant Cell Physiol; 2019 Oct; 60(10):2255-2262. PubMed ID: 31198958
[TBL] [Abstract][Full Text] [Related]
12. Efficient Editing of the Nuclear
Guzmán-Zapata D; Sandoval-Vargas JM; Macedo-Osorio KS; Salgado-Manjarrez E; Castrejón-Flores JL; Oliver-Salvador MDC; Durán-Figueroa NV; Nogué F; Badillo-Corona JA
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30871076
[TBL] [Abstract][Full Text] [Related]
13. Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles.
Liu J; Chang J; Jiang Y; Meng X; Sun T; Mao L; Xu Q; Wang M
Adv Mater; 2019 Aug; 31(33):e1902575. PubMed ID: 31215123
[TBL] [Abstract][Full Text] [Related]
14. CRISPR Guide RNA Design Guidelines for Efficient Genome Editing.
Schindele P; Wolter F; Puchta H
Methods Mol Biol; 2020; 2166():331-342. PubMed ID: 32710418
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 Guide RNA Design Rules for Predicting Activity.
Hiranniramol K; Chen Y; Wang X
Methods Mol Biol; 2020; 2115():351-364. PubMed ID: 32006410
[TBL] [Abstract][Full Text] [Related]
16. gRNA-transient expression system for simplified gRNA delivery in CRISPR/Cas9 genome editing.
Easmin F; Hassan N; Sasano Y; Ekino K; Taguchi H; Harashima S
J Biosci Bioeng; 2019 Sep; 128(3):373-378. PubMed ID: 31010727
[TBL] [Abstract][Full Text] [Related]
17. CRISPR Gene Therapy of the Eye: Targeted Knockout of Vegfa in Mouse Retina by Lentiviral Delivery.
Holmgaard A; Alsing S; Askou AL; Corydon TJ
Methods Mol Biol; 2019; 1961():307-328. PubMed ID: 30912054
[TBL] [Abstract][Full Text] [Related]
18. Optical Control of Genome Editing by Photoactivatable Cas9.
Otabe T; Nihongaki Y; Sato M
Methods Mol Biol; 2021; 2312():225-233. PubMed ID: 34228293
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration.
Koo T; Park SW; Jo DH; Kim D; Kim JH; Cho HY; Kim J; Kim JH; Kim JS
Nat Commun; 2018 May; 9(1):1855. PubMed ID: 29748595
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9-Mediated Gene Silencing in Cultured Human Epithelia.
Gago S; Overton NLD; Bowyer P
Methods Mol Biol; 2021; 2260():37-47. PubMed ID: 33405030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
